APA (7th ed.) Citation

N, T., JH, G., M, T., M, S., Z, P., LP, R., . . . V, H. (2019). Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(10), 3193. https://doi.org/10.1158/1078-0432.CCR-19-1098

Chicago Style (17th ed.) Citation

N, Thatcher, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Rodriguez LP, Breder V, Ostoros G, and Hanes V. "Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 25, no. 10 (2019): 3193. https://doi.org/10.1158/1078-0432.CCR-19-1098.

MLA (9th ed.) Citation

N, Thatcher, et al. "Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 25, no. 10, 2019, p. 3193, https://doi.org/10.1158/1078-0432.CCR-19-1098.